Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) stock closed at $21.20 on 11/30/23 after a major decline of -26.8%. Moreover, exceptionally high trading volume at 549% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has declined -25.3% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, ARWR is expected to continue to be Value Creation neutral.
Arrowhead Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines complementary signals from two proprietary PTR measures of a stock’s attractiveness. Arrowhead Pharmaceuticals has a slightly negative Power Rating of 35 and a very low Appreciation Score of 4, producing the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment